What is the Science on Melatonin for Jet Lag?

Rapid time-zone travel can disrupt circadian rhythms, the body’s 24-hour timing system, and leave sleep out of step with local time (Riedy & Williams, 2025). This mismatch is called jet lag disorder, and it typically resolves on its own at about one time zone per day, more slowly after eastward flights (Arendt, 2018; Riedy & Williams, 2025).

Melatonin is a hormone that helps time sleep, and it is the only jet-lag treatment that the American Academy of Sleep Medicine has endorsed at its highest rating (Morgenthaler et al., 2007; National Center for Complementary and Integrative Health, 2024). Trials suggest it can reduce symptoms for some travelers, although the best dose and timing remain uncertain (Chan et al., 2021; Herxheimer & Petrie, 2002).

This review explains why timing matters more than dose, and summarizes recommendations from sleep and medical societies. It then addresses two questions clinicians ask most often: how to ensure that a product contains what its label claims, and whether any brands can be trusted.

Evidence supports timed melatonin for jet lag, but the trial base is old and small

The American Academy of Sleep Medicine classified appropriately timed melatonin as a Standard treatment for jet lag disorder, the highest rating under its grading system of that era, based on literature available through 2006 (Morgenthaler et al., 2007).

The Cochrane review that anchored this rating included ten older controlled trials involving air travelers or airline personnel (Herxheimer & Petrie, 2002). Nine were judged adequate in quality, and eight of the ten found that melatonin reduced jet lag after flights crossing five or more time zones. Most trials assessed self-reported symptoms, sleep quality, and sleep latency rather than a uniform objective measure of clock adjustment (Herxheimer & Petrie, 2002; Morgenthaler et al., 2007).

An early trial illustrated the potential benefit. Twenty volunteers flying between Auckland and London took 5 mg or placebo for three days before departure, during the flight, and for three days after arrival in a double-blind crossover design (Petrie et al., 1989). Melatonin lowered mean jet-lag ratings from 3.4 to 2.15 on a visual analog scale and shortened the time to a normal sleep pattern from 4.15 to 2.85 days. Jet lag was more severe on the westward return journey than on the eastward outward journey.

A later systematic review pooled five eastbound and four westbound comparisons from ten melatonin studies (Chan et al., 2021). Eastbound trials showed a standardized mean difference of −0.76, a medium-to-large effect, and westbound trials showed a difference of −0.66, a medium effect. These estimates came from older field studies rather than new large trials, and four eligible studies could not be pooled because published data were inadequate. The authors judged the evidence too limited for a firm recommendation.

One eastbound trial assigned 320 travelers crossing six to eight time zones to 0.5 mg or 5 mg immediate-release melatonin, 2 mg controlled-release melatonin, or placebo, taken at destination bedtime for four nights; 234 completed the study (Suhner et al., 1998). Immediate-release melatonin performed better than the controlled-release product. A 0.5 mg dose was almost as effective overall as 5 mg, while 5 mg produced better sleep quality and shorter sleep latency.

Results were not uniformly positive. A randomized trial of 257 Norwegian physicians returning east across six time zones found no advantage for 0.5 mg or 5 mg at bedtime (Spitzer et al., 1999). A shifting 0.5 mg schedule also failed to outperform placebo on jet-lag symptom scores. The old review’s number needed to treat of 2 came from two trials, so it remains an uncertain estimate (Herxheimer & Petrie, 2002). Arendt (2018) described a blinded field program at the University of Surrey in which 474 melatonin users and 112 placebo users reported roughly a 50% average reduction in subjective jet lag with few side effects.

Direct clinical evidence remains limited and is dominated by trials from the 1980s, 1990s, and early 2000s. A French field study randomized 27 travelers after a seven-zone eastbound flight to slow-release caffeine, melatonin, or placebo and found that melatonin improved polysomnographic sleep while caffeine reduced daytime sleepiness (Beaumont et al., 2004).

The Cochrane review’s last search, in February 2008, found no new trials, and no update has been published (Herxheimer & Petrie, 2002). A recent field trial of tasimelteon in 25 eastbound transatlantic travelers was stopped early for slow recruitment and was funded and authored by the manufacturer (Polymeropoulos et al., 2022).

A separate laboratory trial randomized 320 participants to tasimelteon or placebo during a simulated eight-hour phase advance and found about an hour more sleep in the first two-thirds of the night (Polymeropoulos et al., 2020). These studies concern a prescription melatonin-receptor agonist and do not establish the efficacy of supplemental melatonin.

Taken together, trials support melatonin as a useful short-term option for selected travelers, but the likely size of benefit remains uncertain. The studied pattern favors immediate-release dosing near destination sleep. A larger negative study, reliance on self-reported outcomes, and the lack of modern large-scale replication temper confidence (Chan et al., 2021; Herxheimer & Petrie, 2002; Spitzer et al., 1999; Suhner et al., 1998).

Timing determines whether melatonin helps sleep or shifts the clock

Melatonin can act as a chronobiotic, a substance that shifts the timing of circadian rhythms, and as a sleep-promoting signal (Riedy & Williams, 2025; Sack et al., 2007). The body normally begins producing melatonin in the early evening, about two hours before habitual bedtime, an event called the dim light melatonin onset (Burgess et al., 2008; Riedy & Williams, 2025). The phase-response curve describes how the clock time of a dose changes the direction and size of its effect on circadian phase. Realignment with a new light-dark schedule is called circadian re-entrainment.

Eastward travel requires a phase advance, or shift of internal timing earlier. Westward travel requires a phase delay, or shift later. For most people, delay is physiologically easier than advance, so adaptation is generally faster after westward travel (Riedy & Williams, 2025). Early estimates from actual travelers place spontaneous re-entrainment at roughly one hour per day for advances and about 1.5 hours per day for delays (Eastman & Burgess, 2009).

Laboratory phase-response curves make the timing rules concrete. In 27 young adults, 3 mg of melatonin taken about five hours before the dim light melatonin onset produced a maximum advance of 1.8 hours over three days (Burgess et al., 2008). A dose taken about 11 hours after the onset, shortly after usual wake time, produced a maximum delay of 1.3 hours. Doses taken at habitual bedtime or during the first half of sleep fell in a dead zone with little phase-shifting effect.

The authors concluded that bedtime melatonin used as a hypnotic does little to move the clock. That conclusion applies to habitual biological bedtime; after eastward travel, destination bedtime can fall in the biological afternoon or early evening, where the same dose also advances the clock (Burgess et al., 2008; Riedy & Williams, 2025).

A companion study of 0.5 mg in 34 adults found that the maximum advance occurred when the dose was taken in the afternoon, 2 to 4 hours before dim light melatonin onset (Burgess et al., 2010). The best time to take the lower dose was later than for 3 mg, and when each dose was given at its optimal time, the two produced similarly sized advances and delays.

Travelers rarely know their dim light melatonin onset, so practical guidance keys timing to habitual sleep instead. Sleep usually begins about 2.5 hours after the onset, and the core body temperature minimum falls about seven hours after it (Eastman & Burgess, 2009). Mistimed dosing can backfire.

In a trial of 52 international cabin crew, one group began 5 mg three days before the homeward flight and continued for five days after arrival, while another began placebo and switched to 5 mg only after arrival (Petrie et al., 1993). The post-arrival group reported less jet lag and sleep disturbance than placebo, whereas the pre-flight group recovered energy and alertness more slowly than placebo. Arendt (2018) explained the mechanism: when a dose lands on the delay portion of the curve while an advance is needed, the clock may travel the long way around, substituting a 16-hour delay for an 8-hour advance.

The Centers for Disease Control and Prevention advises against taking melatonin at an arbitrary daytime hour (Riedy & Williams, 2025). A dose taken at the wrong circadian phase can cause sleepiness and increase misalignment, and supplemental melatonin is less effective when natural levels are already high, approximately 12 a.m. to 5 a.m. on the traveler’s internal clock. Destination clock time may not match internal time during the first days after a long flight, so the same local dosing time may suit one itinerary and mistime another.

Timing matters at least as much as dose. Dosing near your habitual biological bedtime produces little circadian shifting, but after eastward travel, your destination bedtime may fall in the biological afternoon or early evening, when melatonin can both promote sleep and advance the clock. Dosing near biological wake time delays the clock. A convenient local clock time can still produce unwanted sleepiness or shift the clock in the wrong direction, especially after a large eastward jump (Burgess et al., 2008, 2010; Petrie et al., 1993; Riedy & Williams, 2025).

Combining timed light, sleep scheduling, and melatonin can promote circadian adjustment

Light is the stronger clock-setting signal, and laboratory studies have combined it with melatonin and a gradually shifted sleep schedule. In 44 healthy adults, researchers combined three days of advancing sleep by one hour per day, intermittent bright light on waking, and afternoon melatonin(Revell et al., 2006). The dim light melatonin onset advanced by 2.5 hours with 0.5 mg and 2.6 hours with 3 mg, compared with 1.7 hours for placebo. The two doses did not differ, and participants reported no jet-lag-type symptoms during the protocol.

A later study showed that a single 30-minute morning light pulse, combined with afternoon 0.5 mg melatonin and the same sleep shift, produced about three-quarters of the advance obtained with two hours of light (Crowley & Eastman, 2015).

Light and melatonin combine additively. In a four-arm trial, three hours of bright light beginning one hour before habitual wake time plus 5 mg of melatonin taken about six hours before bedtime produced a larger advance than either cue alone (Burke et al., 2013). The authors concluded that the human clock integrates both signals.

Light can also work against the traveler. After crossing more than eight time zones, local morning light may fall on an unintended part of the light phase-response curve, so the clock may misinterpret dawn as dusk, or vice versa (Riedy & Williams, 2025; Sack, 2010). As a rule of thumb, Sack (2010) suggested avoiding bright light for two to three hours after waking during the first two days after eastward travel, and for two to three hours before dusk after westward travel.

The current CDC chapter sets no fixed timetable; it keys light exposure and avoidance to travel direction, the number of zones crossed, and the traveler’s estimated circadian phase (Riedy & Williams, 2025). Therefore, adjust any light schedule as adaptation proceeds rather than switching it on on a fixed day. The CDC also suggests shifting sleep toward destination time by about one hour per day for two or three days before departure when feasible.

Not every trip calls for adaptation. For stays of two days or less, keeping home-base sleep hours is an accepted option (Morgenthaler et al., 2007; Riedy & Williams, 2025). Arendt (2018) made the same point for short stopovers: preserve sleep and alertness rather than attempt to shift the clock.

Melatonin is one lever among three. Pre-departure sleep shifting, correctly timed light, and low-dose melatonin advanced the clock by nearly an hour per day in laboratory studies, with little misalignment. Those are laboratory phase shifts rather than proof of a superior travel regimen, and light at the wrong time can undo the benefit after very long flights (Burke et al., 2013; Crowley & Eastman, 2015; Revell et al., 2006; Sack, 2010).

A low immediate-release dose is a reasonable starting regimen

Pharmacokinetics explain why low doses suffice. Oral immediate-release melatonin peaks in about 50 minutes and has a half-life near 45 minutes, with oral bioavailability averaging about 15% and ranging from 9% to 33% across studies (Harpsøe et al., 2015). In a small study of adults older than 50, 0.3 mg produced a median peak plasma concentration of about 220 pg/mL, near physiological nighttime levels (Zhdanova et al., 2001). A 3-mg dose produced a median peak of about 1,370 pg/mL and sustained elevation into the following day. Age, caffeine, smoking, oral contraceptives, food, and fluvoxamine all alter exposure (Harpsøe et al., 2015).

Melatonin is most worth considering after five or more time zones, especially eastward, or with prior troublesome jet lag (Herxheimer & Petrie, 2002). The 2021 meta-analysis found symptom reductions after both eastward and westward flights, but each direction-specific estimate rests on few studies (Chan et al., 2021). For adult travelers using melatonin mainly to sleep, a reasonable starting dose is 0.5 to 1 mg of immediate-release melatonin (Riedy & Williams, 2025; Suhner et al., 1998).

The current CDC Yellow Book describes this range as often sufficient to shift circadian timing and illustrates taking it about 90 minutes before bed. Older trials commonly dosed near destination bedtime, often between 10 p.m. and midnight (Herxheimer & Petrie, 2002).

Published regimens converge on a narrow range. Sack (2010) recommended 0.5 to 3 mg nightly until adapted to local time when the goal is to advance the clock, and 0.5 mg during the second half of the night when the goal is to delay it. The United Kingdom’s licensed products specify 3 mg nightly for up to five days, increased to 6 mg if needed, beginning at habitual bedtime on arrival and never before 8 p.m. or after 4 a.m. destination time (Pharma Nord, 2025). The athlete consensus cited 0.5 to 10 mg, described 3 to 5 mg as optimal for sleep onset, and keyed post-flight timing to the estimated core body temperature minimum (Janse van Rensburg et al., 2021). Health Canada’s monograph permits 0.5 to 10 mg once daily at bedtime for jet lag (Health Canada, n.d.).

An evidence-aligned course is one dose on arrival evening and then each local bedtime for three to five nights (Herxheimer & Petrie, 2002; Pharma Nord, 2025). This reflects trial schedules and current travel guidance, not proof that every traveler needs five doses (Herxheimer & Petrie, 2002; Riedy & Williams, 2025). Do not take a missed dose the next morning or add extra daytime doses to catch up.

A 5 mg dose can improve sleep onset and quality more than 0.5 mg, yet the older review found similar jet-lag relief across doses of 0.5 to 5 mg and no added benefit above 5 mg (Herxheimer & Petrie, 2002; Suhner et al., 1998).

The CDC advises against high doses because melatonin may remain elevated at an unhelpful time (Riedy & Williams, 2025). A 2 mg controlled-release preparation was less effective than immediate-release doses in the large dose-form trial (Suhner et al., 1998).

Routine pre-flight dosing is not established. The one trial that compared pre-flight and post-arrival starts favored waiting until arrival (Petrie et al., 1993). An itinerary-based plan may still use pre-travel afternoon doses for a planned advance when combined with earlier sleep and morning light, because that regimen has laboratory support (Crowley & Eastman, 2015; Revell et al., 2006).

For many adults, a low dose of immediate-release melatonin near destination sleep is a sensible starting plan for a few nights. Use an itinerary-specific schedule when the goal is circadian shifting, since direction and internal time change the effect. Doses above 5 mg offer no demonstrated extra jet-lag benefit (Chan et al., 2021; Herxheimer & Petrie, 2002; Riedy & Williams, 2025; Suhner et al., 1998).

Professional societies endorse melatonin for jet lag, with important gaps

The American Academy of Sleep Medicine’s 2007 practice parameter remains its operative jet-lag recommendation. Timed melatonin for jet lag received a Standard rating, the only melatonin indication in that document to reach that level (Morgenthaler et al., 2007). Melatonin for shift work, delayed sleep phase, and non-24-hour disorder in blind individuals received a Guideline rating, and its other circadian uses received an Option rating. The Standard label reflects the Academy’s historical grading system and should not be equated with high certainty under modern GRADE methods.

The recommendation itself names no dose, start day, or direction-specific schedule; the accompanying evidence review discusses doses and schedules without defining one optimal regimen (Morgenthaler et al., 2007; Sack et al., 2007). That review noted that evening melatonin advances and morning melatonin delays the clock, that timing matters more than dose, and that the dose-response above 3 to 5 mg is unclear. It also flagged, nearly two decades ago, that over-the-counter products raise purity and dose-accuracy concerns.

The Academy’s 2015 clinical practice guideline on circadian disorders used modern grading methods but covered only the intrinsic disorders and explicitly left jet lag and shift work unrevised (Auger et al., 2015). A 2021 workshop report cosponsored by the Sleep Research Society and the Society for Research on Biological Rhythms likewise set jet lag aside while noting unresolved concerns about the timing, dosing, potency, and purity of over-the-counter melatonin (Duffy et al., 2021).

The Academy’s only melatonin position statement is a 2022 pediatric health advisory, which urges families to treat melatonin as a medication, consult a clinician, and choose products carrying the USP Verified Mark (Rishi et al., 2023). As of October 2026, the Endocrine Society, the Aerospace Medical Association, and the International Society of Travel Medicine have not issued a position on melatonin for jet lag.

The British Association for Psychopharmacology rated the evidence for melatonin in jet lag disorder at its highest category, based on meta-analysis of randomized trials (Wilson et al., 2019). It recommended melatonin at grade B. The statement cautions that immediate-release melatonin must be taken near the desired bedtime to avoid daytime sleepiness and gives no specific dose or duration. European sleep bodies have published no jet-lag guideline.

The 2023 European insomnia guideline recommends only prolonged-release melatonin for patients aged 55 and older and advises against fast-release melatonin for insomnia (Riemann et al., 2023). At the regulatory level, the European Union authorizes the health claim that melatonin helps alleviate subjective jet lag, provided a product delivers at least 0.5 mg taken close to bedtime on the first day of travel and the following few days (European Commission, 2012).

National regulators diverge. The United Kingdom licensed prescription-only immediate-release melatonin for jet lag in 2019 (“Melatonin for Jet Lag,” 2020). An independent bulletin then concluded that jet lag is self-limiting, that the licensing evidence dates from 1986 to 2005, and that the National Health Service should not routinely fund the drug (“Melatonin for Jet Lag,” 2020; NHS, 2023).

Australia’s Poisons Standard now permits pharmacist-only supply of immediate-release melatonin at 5 mg or less per unit for jet lag in adults 18 and older, in packs of no more than 10 dosage units (Therapeutic Goods Administration, 2026). Pharmacists may also supply 2 mg modified-release tablets for insomnia in people 55 and older, while other melatonin products remain prescription-only.

Canada licenses melatonin as a natural health product with an approved jet-lag claim for eastward travel across two or more time zones (Health Canada, n.d.). In the United States, melatonin is sold as a dietary supplement with no premarket approval (National Center for Complementary and Integrative Health, 2024).

The American Academy of Sleep Medicine’s 2007 parameter assigned appropriately timed melatonin for jet lag a Standard rating under its historical grading system. The British Association for Psychopharmacology’s 2019 statement classified the supporting evidence as category Ia and recommended it as grade B. Both discuss timing, but neither establishes a single optimal regimen. The later Academy advisory addresses safe pediatric use and product quality rather than adult jet-lag efficacy, and regulators classify the same molecule as anything from prescription-only to supplement (Auger et al., 2015; Morgenthaler et al., 2007; Rishi et al., 2023; Wilson et al., 2019).

Short courses are usually tolerated, but precautions matter

Adverse-event data are reassuring for brief use. A systematic review of 37 placebo-controlled trials at doses of 0.15 to 12 mg found daytime sleepiness in 1.66% of participants, with headache, dizziness, and other sleep complaints each below 1%, and no life-threatening events (Besag et al., 2019).

A second review of 50 controlled studies found that most adverse effects were minor and short-lived, chiefly fatigue, mood changes, and reduced psychomotor performance, and that most could be avoided by dosing in line with circadian timing (Foley & Steel, 2019). Long-term safety and safety in at-risk groups remain less clear (Besag et al., 2019; National Center for Complementary and Integrative Health, 2024).

Older adults deserve particular care. Peak melatonin concentrations after a given dose can be substantially higher in older adults than in younger adults, so drowsiness may persist longer (National Center for Complementary and Integrative Health, 2024; Tuft et al., 2023). A review of older-adult use recommended the lowest effective dose, evening rather than daytime dosing, and attention to blood pressure because hypotension and falls have been reported.

Take melatonin only when the traveler can sleep, and avoid driving or safety-sensitive work afterward; Health Canada’s label advises no driving or machinery use for five hours after a dose (Health Canada, n.d.; National Center for Complementary and Integrative Health, 2024).

People who are pregnant or breastfeeding should seek advice because safety data are limited. People with epilepsy should also consult a clinician before use. A review of seizure data found three double-blind trials, two showing no change and one showing fewer seizures, and concluded that melatonin has no marked overall effect on seizures (Jain & Besag, 2013).

Brief use is usually tolerated, with daytime sleepiness the most common complaint. Older age, pregnancy, breastfeeding, and epilepsy call for individualized advice, and no one should drive soon after a dose (Besag et al., 2019; Health Canada, n.d.; Jain & Besag, 2013; Tuft et al., 2023).

Drug and supplement interactions deserve a separate check

Melatonin is cleared mainly by the liver enzyme CYP1A2, so drugs that inhibit or induce that enzyme change exposure more than any other factor (Harpsøe et al., 2015). Fluvoxamine raised melatonin exposure about 17-fold in a small pharmacokinetic study, and product labels advise avoiding the combination (Härtter et al., 2000; Pharma Nord, 2025). Citalopram showed no such effect in the same laboratory, so the interaction appears to involve fluvoxamine rather than

selective serotonin reuptake inhibitors as a class (von Bahr et al., 2000).

Oral contraceptives containing ethinylestradiol raised melatonin exposure four- to fivefold in 29 healthy volunteers (Hilli et al., 2008). Caffeine, 600 mg taken with a 6 mg dose, more than doubled melatonin exposure, with the larger effect in nonsmokers (Härtter et al., 2003). Labels also list cimetidine, quinolone antibiotics, and 5- or 8-methoxypsoralen as agents that can raise levels (Pharma Nord, 2025).

Inducers push the other way. Cigarette smoking induces CYP1A2, and in eight smokers exposure to a 25 mg oral dose was about three times higher after a week of abstinence than while smoking, although nighttime endogenous levels were unchanged (Ursing et al., 2005). Carbamazepine and rifampicin are listed as inducers that may lower melatonin concentrations (Pharma Nord, 2025). A traveler who stops smoking on a long trip, or who starts or stops an interacting drug, may find that a familiar dose behaves differently.

Cardiovascular drugs need attention. In 47 patients with hypertension controlled by nifedipine, 5 mg of melatonin at bedtime for four weeks raised 24-hour systolic pressure by 6.5 mmHg, diastolic pressure by 4.9 mmHg, and heart rate by about four beats per minute (Lusardi et al., 2000). The United Kingdom label therefore cautions against combining melatonin with nifedipine and advises care with other calcium channel blockers (Pharma Nord, 2025).

Beta-blockers act on endogenous melatonin instead: single doses of propranolol or atenolol cut nocturnal melatonin excretion by 80% or more in healthy volunteers (Stoschitzky et al., 1999). That suppression helps explain sleep complaints on beta-blockers and does not by itself make supplementation unsafe, but the combination has not been studied in travelers. Blood pressure effects more broadly depend on dose, timing, and concurrent antihypertensive drugs (Foley & Steel, 2019).

Anticoagulants, sedatives, and alcohol carry label warnings. The warfarin concern rests on six suspected case reports of reduced prothrombin activity or bleeding, so more frequent monitoring of the international normalized ratio is prudent when melatonin starts or stops (Herxheimer & Petrie, 2002; Tuft et al., 2023). In a field trial, melatonin plus zolpidem was less well tolerated than melatonin alone, with confusion, morning sleepiness, and nausea most frequent in the combined group (Suhner et al., 2001).

In healthy adults over 55, prolonged-release melatonin alone did not impair driving or memory tests, but adding it to zolpidem worsened zolpidem’s impairment one and four hours after dosing (Otmani et al., 2008). Labels advise avoiding benzodiazepines and related hypnotics, and they advise against alcohol because it reduces melatonin’s effect on sleep (Pharma Nord, 2025). A moderate evening dose of alcohol also suppressed endogenous melatonin by 15% to 19% in young adults (Rupp et al., 2007).

Other combinations are untested, not proven safe. The immunosuppressant interaction is theoretical, resting on melatonin’s immune-stimulating properties rather than reported cases, yet Health Canada’s monograph advises consulting a practitioner before combining them (Health Canada, n.d.).

The same monograph advises against taking melatonin with other products that cause drowsiness, which covers valerian, kava, tryptophan, 5-hydroxytryptophan, and cannabidiol, none of which have been tested with melatonin in humans. Cannabidiol altered melatonin absorption in mice at high doses, but no human data exist (Wang et al., 2024). Anticoagulant users and anyone taking several interacting drugs should check with a pharmacist before travel (National Center for Complementary and Integrative Health, 2024).

Interactions are few but specific. Fluvoxamine, oral contraceptives, caffeine, and quinolones raise melatonin exposure; smoking, carbamazepine, and rifampicin lower it; nifedipine, warfarin, hypnotics, and alcohol carry label warnings backed by at least one controlled study or case series. Most other combinations are untested rather than proven safe (Härtter et al., 2000; Hilli et al., 2008; Lusardi et al., 2000; Otmani et al., 2008; Pharma Nord, 2025).

Product quality is the weak link: how to ensure purity and dose

In the United States, the Food and Drug Administration does not approve supplements for safety or effectiveness before they are marketed (National Center for Complementary and Integrative Health, 2024). Manufacturers must comply with current good manufacturing practice regulations, which require ingredient specifications and finished-batch testing, and the agency enforces them through inspections and other post-market oversight rather than premarket review (U.S. Food and Drug Administration, 2026).

An editorial accompanying the first large content analysis concluded that there is no guarantee of the strength or purity of over-the-counter melatonin and noted that most other high-income countries treat it as a prescription drug (Grigg-Damberger & Ianakieva, 2017).

The content data are sobering. A Canadian laboratory tested 31 products from 16 brands and found melatonin ranging from 83% below to 478% above the label (Erland & Saxena, 2017). Lot-to-lot variation within one product reached 465%. Eight products, about one in four, also contained serotonin, a chemical messenger that is not a declared ingredient and has no place in a sleep aid.

A 2023 analysis of 25 melatonin gummies sold in the United States found that 22 were inaccurately labeled, with content from 74% to 347% of the claim (Cohen et al., 2023). Five of the gummies listed cannabidiol as an ingredient, and one contained no detectable melatonin despite its label.

Later surveys show the same pattern. Food and Drug Administration chemists analyzed 110 products, mostly marketed for children, and found content ranging from 0% to 667% of the label claim (Pawar et al., 2025). Half of the products fell within 23% of their claim, and 20 contained less than three-quarters of it.

A Belgian study of 50 products bought online found label accuracy from 71% to 182% among legally sold products, while every product from suspicious sellers exceeded the national daily limit, with servings as high as 23 mg (Vanhee et al., 2025).

Neither recent survey detected serotonin, but these studies sampled different products and markets and therefore cannot establish whether serotonin contamination has declined over time (Cohen et al., 2023; Pawar et al., 2025).

Unsupervised pediatric ingestion is a separate safety concern. United States poison centers received 260,435 reports of pediatric melatonin ingestion during 2012 to 2021, and annual reports rose 530%, from 8,337 to 52,563 (Lelak et al., 2022). The reports included 4,097 hospitalizations and two deaths in children younger than two, although the data could not establish whether melatonin alone caused either death.

An estimated 10,930 emergency department visits for unsupervised ingestion occurred in children five and younger between 2019 and 2022, and gummies accounted for nearly half (Freeman et al., 2024). In response, the Council for Responsible Nutrition adopted voluntary guidelines in 2024 calling for drowsiness and alcohol warnings, intermittent-use labeling, child-deterrent packaging for flavored chewables, and overages supported by stability data (Council for Responsible Nutrition, 2024).

Third-party certification is the practical safeguard. The USP Verified Mark certifies that a product contains the labeled ingredients in the declared amounts, is free of harmful levels of specified contaminants, and will dissolve within a specified time (United States Pharmacopeia, n.d.). It also confirms manufacture under good manufacturing practice and includes off-the-shelf retesting.

NSF certification to the NSF/ANSI 173 standard verifies label claims, screens for contaminants and undeclared ingredients, and audits facilities annually; the NSF Certified for Sport program adds screening for about 280 banned substances (NSF, n.d.-a).

ConsumerLab independently purchases and tests products and reported that all 20 melatonin products it tested in 2024 contained the labeled amount within a reasonable margin (ConsumerLab, 2024). The American Academy of Sleep Medicine’s advisory specifically recommends products carrying the USP Verified Mark (Rishi et al., 2023).

Label accuracy cannot be assumed. Across four independent surveys, a large share of over-the-counter melatonin products missed their label by more than 10%, some by severalfold, and a few contained undeclared serotonin. Independent verification by USP, NSF, or ConsumerLab raises confidence in the attributes tested, provided the exact product and strength appear in the organization’s current listing, but it does not establish effectiveness or safety for an individual traveler (Cohen et al., 2023; Erland & Saxena, 2017; Pawar et al., 2025; Rishi et al., 2023).

Are there trusted brands?

No brand is trustworthy on reputation alone, but certifier lists identify products that have passed independent testing. As of October 2026, Nature Made lists its melatonin 3 mg and 5 mg tablets as USP Verified (Nature Made, n.d.). NSF Certified for Sport listings include Thorne Melaton-3, a 3 mg capsule, and Klean Melatonin from Klean Athlete, along with several multi-ingredient sleep formulas (NSF, n.d.-b). ConsumerLab’s quality certification program passed GNC Melatonin 3 mg and the Nature’s Way melatonin lozenge in its 2024 cycle (ConsumerLab, 2024). Certifier lists change, so clinicians should check the current USP, NSF, or ConsumerLab listing rather than rely on this snapshot.

Certified low doses take more searching. The USP-verified and NSF-certified products identified above are all 3 mg or 5 mg. ConsumerLab’s 2024 round, however, included products as low as 0.3 mg, and all 20 passed its content test, so independently tested low-dose options exist (ConsumerLab, 2024). Seek an immediate-release product that combines the intended dose with credible, product-specific independent testing, and do not choose a higher dose solely because it carries a particular mark.

Formulation still deserves attention. Substantial label inaccuracies have been documented in melatonin gummies, and gummies accounted for nearly half of pediatric emergency visits for unsupervised ingestion in one surveillance study, although those data do not establish their risk relative to other forms (Cohen et al., 2023; Freeman et al., 2024).

Product-specific quality testing and secure storage matter for every formulation. Immediate-release products are better supported than controlled-release products for jet lag (Suhner et al., 1998). Products combining melatonin with other sedating ingredients add unstudied variables and are best avoided.

Where a pharmaceutical product is available, it removes the guesswork. The United Kingdom licenses 3 mg immediate-release tablets and a 1 mg/mL oral solution for jet lag on prescription, with the oral solution allowing precise low-dose titration (“Melatonin for Jet Lag,” 2020; Pharma Nord, 2025). Canadian products carry a natural product number that signals a licensed facility and a government-reviewed label (Health Canada, n.d.).

In the United States, a compounding pharmacy can prepare custom strengths on prescription, although compounded products are not FDA-approved and quality depends on the pharmacy. Whatever the source, store melatonin out of the reach of children and in child-resistant packaging (Lelak et al., 2022; Rishi et al., 2023).

Trust the certifier, not the brand. Choose an immediate-release tablet or capsule bearing a current USP, NSF, or ConsumerLab mark, or a licensed pharmaceutical product where one exists, and verify the listing at the time of purchase. Match the intended dose to a product with current, product-specific independent testing rather than raising the dose to obtain a certification mark (ConsumerLab, 2024; Nature Made, n.d.; NSF, n.d.-b).

Integrative summary

The evidence supports short-term melatonin for adult travelers who need help sleeping and adjusting to local time after crossing several time zones. Start with a low immediate-release dose near destination bedtime and use it only for the first few nights. To shift the internal clock, use an itinerary-specific schedule that accounts for travel direction, light, and circadian phase, and combine melatonin with pre-departure sleep shifting and correctly timed light. Check for interacting drugs, especially fluvoxamine, oral contraceptives, nifedipine, warfarin, and hypnotics, and choose an independently tested product before dosing. The trial evidence is old, the society ratings date from 2007 and 2019, and the supplement on the shelf may not contain what its label claims (Burgess et al., 2008; Chan et al., 2021; Erland & Saxena, 2017; Herxheimer & Petrie, 2002; Morgenthaler et al., 2007; Riedy & Williams, 2025).

Key takeaways

1. Melatonin can help some adult travelers, with the clearest traditional evidence after long eastward journeys and newer evidence suggesting benefit in both directions, although the direct evidence is dominated by trials from the 1980s to the early 2000s.

2. A 0.5 to 1 mg immediate-release dose at destination bedtime is a reasonable starting point for sleep; a dose near habitual biological bedtime does little to move the clock, but after eastward travel destination bedtime may fall in the biological afternoon or early evening, where the same dose also advances the clock.

3. Combine melatonin with sleep shifted toward destination time before departure and with correctly timed light, and avoid starting melatonin before the flight unless the regimen is itinerary-specific.

4. Sleep societies endorse timed melatonin for jet lag, with an AASM Standard rating in 2007 and a BAP grade B recommendation on category Ia evidence in 2019, but neither defines a single regimen, and the newest statements emphasize product quality over efficacy.

5. Independent surveys show that many melatonin products miss their label by more than 10%; choose an immediate-release product at the intended dose with current, product-specific testing by USP, NSF, or ConsumerLab, or a licensed pharmaceutical product, and keep it away from children.

Glossary

bioavailability: the fraction of an oral dose that reaches the bloodstream unchanged.

chronobiotic: a substance that changes the timing of circadian rhythms.

circadian phase: the timing of an internal daily rhythm relative to the local day and night.

circadian re-entrainment: the process by which internal rhythms become aligned with a new light-dark schedule.

circadian rhythm: an internal biological pattern that repeats on an approximately 24-hour cycle.

controlled-release melatonin: melatonin supplied in a dosage form designed to release it over a longer period.

core body temperature minimum: the lowest point of the daily body-temperature rhythm, usually occurring during the second half of sleep and marking the turning point between delay and advance responses to light.

current good manufacturing practice: the federal regulations that set requirements for how dietary supplements are manufactured, tested, labeled, and stored.

CYP1A2: a liver enzyme that metabolizes melatonin; drugs that inhibit it can raise melatonin levels.

dietary supplement: a product intended to supplement the diet and regulated differently from a drug in the United States.

dim light melatonin onset: the time in the evening when melatonin secretion begins, measured under dim light; the most widely used marker of circadian phase.

half-life: the time required for a drug concentration in the blood to fall by half.

hypnotic: a drug or substance that promotes sleep.

immediate-release melatonin: melatonin supplied in a dosage form that releases it relatively quickly rather than over an extended period.

international normalized ratio: a standardized measure of blood clotting time used to monitor warfarin therapy.

jet lag disorder: sleep and daytime symptoms caused by rapid travel across time zones and resulting mismatch with local time.

melatonin: a hormone produced mainly during darkness that helps time circadian rhythms and sleep.

number needed to treat: the number of people who must receive an intervention for one additional person to benefit compared with a control condition.

phase advance: a shift of circadian timing earlier.

phase delay: a shift of circadian timing later.

phase-response curve: a description of how the timing of an intervention determines the direction and size of a circadian shift.

randomized trial: a study that assigns participants to treatment groups by chance.

self-reported outcomes: symptoms or experiences rated by participants rather than measured only by an instrument.

serotonin: a chemical messenger that helps transmit signals in the nervous system.

sleep latency: the time between trying to sleep and falling asleep.

standardized mean difference: an effect-size measure that expresses a difference between groups in standard-deviation units.

USP Verified Mark: a voluntary certification from the United States Pharmacopeia indicating that a supplement contains its labeled ingredients in the declared amounts, is free of harmful contaminant levels, dissolves properly, and was made under good manufacturing practice.

References

Arendt, J. (2018). Approaches to the pharmacological management of jet lag. Drugs, 78(14), 1419–1431. https://doi.org/10.1007/s40265-018-0973-8

Auger, R. R., Burgess, H. J., Emens, J. S., Deriy, L. V., Thomas, S. M., & Sharkey, K. M. (2015). Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: Advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An update for 2015: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 11(10), 1199–1236. https://doi.org/10.5664/jcsm.5100

Beaumont, M., Batéjat, D., Piérard, C., Van Beers, P., Denis, J. B., Coste, O., Doireau, P., Chauffard, F., French, J., & Lagarde, D. (2004). Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. Journal of Applied Physiology, 96(1), 50–58. https://doi.org/10.1152/japplphysiol.00940.2002

Besag, F. M. C., Vasey, M. J., Lao, K. S. J., & Wong, I. C. K. (2019). Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: A systematic review. CNS Drugs, 33(12), 1167–1186. https://doi.org/10.1007/s40263-019-00680-w

Burgess, H. J., Revell, V. L., & Eastman, C. I. (2008). A three pulse phase response curve to three milligrams of melatonin in humans. The Journal of Physiology, 586(2), 639–647. https://doi.org/10.1113/jphysiol.2007.143180

Burgess, H. J., Revell, V. L., Molina, T. A., & Eastman, C. I. (2010). Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. The Journal of Clinical Endocrinology & Metabolism, 95(7), 3325–3331. https://doi.org/10.1210/jc.2009-2590

Burke, T. M., Markwald, R. R., Chinoy, E. D., Snider, J. A., Bessman, S. C., Jung, C. M., & Wright, K. P., Jr. (2013). Combination of light and melatonin time cues for phase advancing the human circadian clock. Sleep, 36(11), 1617–1624. https://doi.org/10.5665/sleep.3110

Chan, V., Wang, L., & Allman-Farinelli, M. (2021). Efficacy of functional foods, beverages, and supplements claiming to alleviate air travel symptoms: Systematic review and meta-analysis. Nutrients, 13(3), 961. https://doi.org/10.3390/nu13030961

Cohen, P. A., Avula, B., Wang, Y.-H., Katragunta, K., & Khan, I. (2023). Quantity of melatonin and CBD in melatonin gummies sold in the US. JAMA, 329(16), 1401–1402. https://doi.org/10.1001/jama.2023.2296

ConsumerLab. (2024, February 1). Best melatonin supplements 2024. https://www.consumerlab.com/news/best-melatonin-supplements-2024/02-01-2024/

Council for Responsible Nutrition. (2024, April 15). CRN adopts new guidelines for melatonin supplements to promote responsible usage [Press release]. https://www.crnusa.org/newsroom/crn-adopts-new-guidelines-melatonin-supplements-promote-responsible-usage

Crowley, S. J., & Eastman, C. I. (2015). Phase advancing human circadian rhythms with morning bright light, afternoon melatonin, and gradually shifted sleep: Can we reduce morning bright-light duration? Sleep Medicine, 16(2), 288–297. https://doi.org/10.1016/j.sleep.2014.12.004

Duffy, J. F., Abbott, S. M., Burgess, H. J., Crowley, S. J., Emens, J. S., Epstein, L. J., Gamble, K. L., Hasler, B. P., Kristo, D. A., Malkani, R. G., Rahman, S. A., Thomas, S. J., Wyatt, J. K., Zee, P. C., & Klerman, E. B. (2021). Workshop report. Circadian rhythm sleep-wake disorders: Gaps and opportunities. Sleep, 44(5), Article zsaa281. https://doi.org/10.1093/sleep/zsaa281

Eastman, C. I., & Burgess, H. J. (2009). How to travel the world without jet lag. Sleep Medicine Clinics, 4(2), 241–255. https://doi.org/10.1016/j.jsmc.2009.02.006

Erland, L. A. E., & Saxena, P. K. (2017). Melatonin natural health products and supplements: Presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine, 13(2), 275–281. https://doi.org/10.5664/jcsm.6462

European Commission. (2012). Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health. Official Journal of the European Union, L 136, 1–40. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32012R0432

Foley, H. M., & Steel, A. E. (2019). Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence. Complementary Therapies in Medicine, 42, 65–81. https://doi.org/10.1016/j.ctim.2018.11.003

Freeman, D. I., Lind, J. N., Weidle, N. J., Geller, A. I., Stone, N. D., & Lovegrove, M. C. (2024). Notes from the field: Emergency department visits for unsupervised pediatric melatonin ingestion — United States, 2019–2022. MMWR. Morbidity and Mortality Weekly Report, 73(9), 215–217. https://doi.org/10.15585/mmwr.mm7309a5

Grigg-Damberger, M. M., & Ianakieva, D. (2017). Poor quality control of over-the-counter melatonin: What they say is often not what you get. Journal of Clinical Sleep Medicine, 13(2), 163–165. https://doi.org/10.5664/jcsm.6434

Harpsøe, N. G., Andersen, L. P. H., Gögenur, I., & Rosenberg, J. (2015). Clinical pharmacokinetics of melatonin: A systematic review. European Journal of Clinical Pharmacology, 71(8), 901–909. https://doi.org/10.1007/s00228-015-1873-4

Härtter, S., Grözinger, M., Weigmann, H., Röschke, J., & Hiemke, C. (2000). Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clinical Pharmacology & Therapeutics, 67(1), 1–6. https://doi.org/10.1067/mcp.2000.104071

Härtter, S., Nordmark, A., Rose, D.-M., Bertilsson, L., Tybring, G., & Laine, K. (2003). Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. British Journal of Clinical Pharmacology, 56(6), 679–682. https://doi.org/10.1046/j.1365-2125.2003.01933.x

Health Canada. (n.d.). Melatonin – Oral [Natural Health Products Ingredients Database monograph]. https://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=136

Herxheimer, A., & Petrie, K. J. (2002). Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews, 2002(2), Article CD001520. https://doi.org/10.1002/14651858.CD001520

Hilli, J., Korhonen, T., Turpeinen, M., Hokkanen, J., Mattila, S., & Laine, K. (2008). The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism. The Journal of Clinical Pharmacology, 48(8), 986–994. https://doi.org/10.1177/0091270008318669

Jain, S., & Besag, F. M. C. (2013). Does melatonin affect epileptic seizures? Drug Safety, 36(4), 207–215. https://doi.org/10.1007/s40264-013-0033-y

Janse van Rensburg, D. C., Jansen van Rensburg, A., Fowler, P. M., Bender, A. M., Stevens, D., Sullivan, K. O., Fullagar, H. H. K., Alonso, J.-M., Biggins, M., Claassen-Smithers, A., Collins, R., Dohi, M., Driller, M. W., Dunican, I. C., Gupta, L., Halson, S. L., Lastella, M., Miles, K. H., Nedelec, M., ... Botha, T. (2021). Managing travel fatigue and jet lag in athletes: A review and consensus statement. Sports Medicine, 51(10), 2029–2050. https://doi.org/10.1007/s40279-021-01502-0

Lelak, K., Vohra, V., Neuman, M. I., Toce, M. S., & Sethuraman, U. (2022). Pediatric melatonin ingestions — United States, 2012–2021. MMWR. Morbidity and Mortality Weekly Report, 71(22), 725–729. https://doi.org/10.15585/mmwr.mm7122a1

Lusardi, P., Piazza, E., & Fogari, R. (2000). Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: A 24-hour study. British Journal of Clinical Pharmacology, 49(5), 423–427. https://doi.org/10.1046/j.1365-2125.2000.00195.x

Melatonin for jet lag. (2020). Drug and Therapeutics Bulletin, 58(2), 21–24. https://doi.org/10.1136/dtb.2019.000074

Morgenthaler, T. I., Lee-Chiong, T., Alessi, C., Friedman, L., Aurora, R. N., Boehlecke, B., Brown, T., Chesson, A. L., Jr., Kapur, V., Maganti, R., Owens, J., Pancer, J., Swick, T. J., & Zak, R. (2007). Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders: An American Academy of Sleep Medicine report. Sleep, 30(11), 1445–1459. https://doi.org/10.1093/sleep/30.11.1445

National Center for Complementary and Integrative Health. (2024, May). Melatonin: What you need to know. National Institutes of Health. https://www.nccih.nih.gov/health/melatonin-what-you-need-to-know

Nature Made. (n.d.). USP verified. https://www.naturemade.com/pages/usp-verified

NHS. (2023, May 31). Jet lag. https://www.nhs.uk/conditions/jet-lag/

NSF. (n.d.-a). Supplement and vitamin certification. https://www.nsf.org/consumer-resources/articles/supplement-vitamin-certification

NSF. (n.d.-b). NSF Certified for Sport: Search results for melatonin. https://www.nsfsport.com/certified-products/search-results.php?keyword=melatonin

Otmani, S., Demazières, A., Staner, C., Jacob, N., Nir, T., Zisapel, N., & Staner, L. (2008). Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Human Psychopharmacology: Clinical and Experimental, 23(8), 693–705. https://doi.org/10.1002/hup.980

Pawar, R. S., Coppin, J. P., Khanna, S., & Parker, C. H. (2025). A survey of melatonin in dietary supplement products sold in the United States. Drug Testing and Analysis, 17(8), 1176–1185. https://doi.org/10.1002/dta.3823

Petrie, K., Conaglen, J. V., Thompson, L., & Chamberlain, K. (1989). Effect of melatonin on jet lag after long haul flights. BMJ, 298(6675), 705–707. https://doi.org/10.1136/bmj.298.6675.705

Petrie, K., Dawson, A. G., Thompson, L., & Brook, R. (1993). A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biological Psychiatry, 33(7), 526–530. https://doi.org/10.1016/0006-3223(93)90007-Z

Pharma Nord. (2025). Syncrodin 3 mg film-coated tablets: Summary of product characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/101253/smpc

Polymeropoulos, C. M., Mohrman, M. A., Keefe, M. S., Brzezynski, J. L., Wang, J., Prokosch, L. S., Polymeropoulos, V. M., Xiao, C., Birznieks, G., & Polymeropoulos, M. H. (2020). Efficacy of tasimelteon (HETLIOZ®) in the treatment of jet lag disorder evaluated in an 8-h phase advance model; a multicenter, randomized, double-blind, placebo-controlled trial. Frontiers in Neurology, 11, Article 611. https://doi.org/10.3389/fneur.2020.00611

Polymeropoulos, C. M., Polymeropoulos, V. M., Czeisler, E. L., Fisher, M. A., Smieszek, S. P., Xiao, C., Birznieks, G., & Polymeropoulos, M. H. (2022). Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial. Frontiers in Neurology, 13, Article 901467. https://doi.org/10.3389/fneur.2022.901467

Revell, V. L., Burgess, H. J., Gazda, C. J., Smith, M. R., Fogg, L. F., & Eastman, C. I. (2006). Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light. The Journal of Clinical Endocrinology & Metabolism, 91(1), 54–59. https://doi.org/10.1210/jc.2005-1009

Riedy, S. M., & Williams, S. G. (2025). Jet lag disorder. In CDC Yellow Book 2026: Health information for international travel. Centers for Disease Control and Prevention. https://www.cdc.gov/yellow-book/hcp/travel-air-sea/jet-lag-disorder.html

Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., Dolenc Groselj, L., Ellis, J. G., Garcia-Borreguero, D., Geoffroy, P. A., Gjerstad, M., Gonçalves, M., Hertenstein, E., Hoedlmoser, K., Hion, T., ... Spiegelhalder, K. (2023). The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research, 32(6), Article e14035. https://doi.org/10.1111/jsr.14035

Rishi, M. A., Khosla, S., Sullivan, S. S., & the Public Safety and the Public Awareness Advisory Committees of the American Academy of Sleep Medicine. (2023). Health advisory: Melatonin use in children. Journal of Clinical Sleep Medicine, 19(2), 415. https://doi.org/10.5664/jcsm.10332

Rupp, T. L., Acebo, C., & Carskadon, M. A. (2007). Evening alcohol suppresses salivary melatonin in young adults. Chronobiology International, 24(3), 463–470. https://doi.org/10.1080/07420520701420675

Sack, R. L. (2010). Jet lag. The New England Journal of Medicine, 362(5), 440–447. https://doi.org/10.1056/NEJMcp0909838

Sack, R. L., Auckley, D., Auger, R. R., Carskadon, M. A., Wright, K. P., Jr., Vitiello, M. V., & Zhdanova, I. V. (2007). Circadian rhythm sleep disorders: Part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. Sleep, 30(11), 1460–1483. https://doi.org/10.1093/sleep/30.11.1460

Spitzer, R. L., Terman, M., Williams, J. B. W., Terman, J. S., Malt, U. F., Singer, F., & Lewy, A. J. (1999). Jet lag: Clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial. American Journal of Psychiatry, 156(9), 1392–1396. https://doi.org/10.1176/ajp.156.9.1392

Stoschitzky, K., Sakotnik, A., Lercher, P., Zweiker, R., Maier, R., Liebmann, P., & Lindner, W. (1999). Influence of beta-blockers on melatonin release. European Journal of Clinical Pharmacology, 55(2), 111–115. https://doi.org/10.1007/s002280050604

Suhner, A., Schlagenhauf, P., Höfer, I., Johnson, R., Tschopp, A., & Steffen, R. (2001). Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviation, Space, and Environmental Medicine, 72(7), 638–646. https://pubmed.ncbi.nlm.nih.gov/11471907/

Suhner, A., Schlagenhauf, P., Johnson, R., Tschopp, A., & Steffen, R. (1998). Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiology International, 15(6), 655–666. https://doi.org/10.3109/07420529808993201

Therapeutic Goods Administration. (2026). Consultation: Proposed amendments to the Poisons Standard. Pre-meeting public notice, ACMS #49, March 2026. Australian Government Department of Health. https://consultations.tga.gov.au/tga/scheduling-pre-meeting-march-2026/user_uploads/pmpn---march-2026.pdf

Tuft, C., Matar, E., Menczel Schrire, Z., Grunstein, R. R., Yee, B. J., & Hoyos, C. M. (2023). Current insights into the risks of using melatonin as a treatment for sleep disorders in older adults. Clinical Interventions in Aging, 18, 49–59. https://doi.org/10.2147/CIA.S361519

United States Pharmacopeia. (n.d.). USP Verified Mark. https://www.usp.org/verification-services/verified-mark

Ursing, C., von Bahr, C., Brismar, K., & Röjdmark, S. (2005). Influence of cigarette smoking on melatonin levels in man. European Journal of Clinical Pharmacology, 61(3), 197–201. https://doi.org/10.1007/s00228-005-0908-7

U.S. Food and Drug Administration. (2026, August 27). Questions and answers on dietary supplements. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements

Vanhee, C., Degrève, C., Boschmans, N., Naïmi, Y., Canfyn, M., Deconinck, E., & Willocx, M. (2025). Validated UHPLC methods for melatonin quantification reveal regulatory violations in EU online dietary supplements commerce. Molecules, 30(12), Article 2647. https://doi.org/10.3390/molecules30122647

von Bahr, C., Ursing, C., Yasui, N., Tybring, G., Bertilsson, L., & Röjdmark, S. (2000). Fluvoxamine but not citalopram increases serum melatonin in healthy subjects: An indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. European Journal of Clinical Pharmacology, 56(2), 123–127. https://doi.org/10.1007/s002280050729

Wang, M., Zhang, W., Wu, X., Wang, L., Li, C., Liu, C., & Zhuang, X. (2024). LC-MS/MS-based concurrent quantification of cannabidiol and melatonin in mouse plasma to elucidate complex PK interactions. Pharmaceutics, 16(12), Article 1511. https://doi.org/10.3390/pharmaceutics16121511

Wilson, S., Anderson, K., Baldwin, D., Dijk, D.-J., Espie, A., Espie, C., Gringras, P., Krystal, A., Nutt, D., Selsick, H., & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. Journal of Psychopharmacology, 33(8), 923–947. https://doi.org/10.1177/0269881119855343

Zhdanova, I. V., Wurtman, R. J., Regan, M. M., Taylor, J. A., Shi, J. P., & Leclair, O. U. (2001). Melatonin treatment for age-related insomnia. The Journal of Clinical Endocrinology & Metabolism, 86(10), 4727–4730. https://doi.org/10.1210/jcem.86.10.7901